Expression features of targets for anti-glioma CAR-T cell immunotherapy
- 28 October 2024
- journal article
- research article
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 171 (1) , 179-189
Abstract
Objective To investigate the expression features of common anti-glioma CAR-T targets (B7H3, CSPG4, EGFRv III, HER2 and IL-13Ra2) in gliomas with different grades and molecular subtypes, and explore the association of target expression with glioma malignant or immune phenotypes including immune evasion, stemness, antigen presentation, and tumor angiogenesis. Methods Opal™ Multiplex immunofluorescence staining was performed on glioma tissues to detect the expression of targets, and biomarkers related to the phenotypes. Results High variety of CAR-T target expression among glioma subtypes was observed. GBMs exhibited the highest expression level of all the examined targets among glioma subtypes. In all glioma cases, CSPG4 was the most prevalent target covering over 84% glioma cases, followed by B7H3 at over 64%. B7H3 exhibited the highest coverage (94%) in GBMs while CSPG4 was the most popular target in both oligodendrogliomas and astrocytomas, covering 94% and 80% cases, respectively. Bi or tri-target combination strategies markedly expanded the tumor coverage across glioma cases while increased tumor-cell coverage within tumor. PD-L1 expression was significantly enriched in all the target-positive cells (except the EGFRvIII+ cells); CD133 expression was higher in the CSPG4+ or IL-13Ra2+ cells, and CD31 elevated in the B7H3+ cells, as compared with their negative cell populations. Conclusion Anti-glioma CAR-T targets have heterogenous expression and distinct tumor coverage among glioma subtypes, and closely correlate with glioma malignant or immune phenotypes.Keywords
Funding Information
- The capital health research and development of special (2022YFC2403905)
- The capital health research and development of special (2022-2-2047)
- National Natural Science Foundation of China (81930048)
This publication has 50 references indexed in Scilit:
- Chondroitin sulfate modification of CSPG4 regulates the maintenance and differentiation of glioma-initiating cells via integrin-associated signalingJournal of Biological Chemistry, 2024
- The Rational Development of CD133-Targeting Immunotherapies for GlioblastomaCell Stem Cell, 2020
- EGFRvIII-CAR-T Cells with PD-1 Knockout Have Improved Anti-Glioma ActivityPathology and Oncology Research, 2020
- The natural HLA ligandome of glioblastoma stem-like cells: antigen discovery for T cell-based immunotherapyActa Neuropathologica, 2018
- HER2-Specific Chimeric Antigen Receptor–Modified Virus-Specific T Cells for Progressive GlioblastomaJAMA Oncology, 2017
- The Microenvironmental Landscape of Brain TumorsCancer Cell, 2017
- T cells redirected to interleukin-13Rα2 with interleukin-13 mutein–chimeric antigen receptors have anti-glioma activity but also recognize interleukin-13Rα1Cytotherapy, 2014
- Combinational Targeting Offsets Antigen Escape and Enhances Effector Functions of Adoptively Transferred T Cells in GlioblastomaMolecular Therapy, 2013
- Genes that Distinguish Physiological and Pathological AngiogenesisCancer Cell, 2007
- Escape of Human Solid Tumors from T–Cell Recognition: Molecular Mechanisms and Functional Significance1999